Diligence memo · auto-generated · as of July 3, 2026
Ostentus Therapeutics, Inc.
Ostentus Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Ostentus Therapeutics, Inc. operates in Pharma, based in NEWPORT COAST.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ostentus Therapeutics, Inc. has raised $1.8M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $520K on 2022-10-04.
Most recent recorded round closed around 2024-02-24.
Valuation (modeled)modeled
Provath models Ostentus Therapeutics, Inc. at approximately $835K (range $84K–$3.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 2.4 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round was 3.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 42% of Pharma peers (310 compared).
Modeled value ranks above 20% of those peers.
Closest niche peers: Acanna Therapeutics, Inc., Neural Therapeutics Inc., Insignis Therapeutics Inc., Atacama Therapeutics, Inc., Pharma Acuity, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.